PhD, 10 years of academic research experience, 4 years project management experience and corporate business development, 7 years as CEO in the biotech sector from the beginning up to the stage of development (Advancell and ERABiotech.) He is CEO of Janus and is responsible for business development (relationship with potential customers and generating new opportunities for in-licensing) and interim management.

Chemical Engineer, MBA IESE (Class of 2000), technical expertise in the pharmaceutical industry (Almirall), 7 years in the Fundació Bosch i Gimpera Foundation, Office of Technology Transfer at the University of Barcelona, the last 4 years as Area manager, responsible for licensing technologies and support spin-offs from the UB. She is the CFO, and responsible for economic evaluation of new projects, consultancy and interim management.

7 years in R&D experience in vitro diagnostics, 6 years basic research and teaching, with more than 13 years experience in project management and planning in the pharmaceutical industry, from preclinical stage to commercialization (Almirall). He is the COO of Janus, responsible for development of projects: assessment, planning and implementation of projects and interim management and consulting services.

Dr. Gill has over 28 years of strategic
management, research, and technology commercialization experience in the life sciences industry, with key top executive roles in Truetouch, ProNAi Therapeutics,Signet
Laboratories, AnVil, ActiveCyte, Genome Therapeutics
Corp; now Oscient Pharmaceuticals (NASDAQ: OSCI), and BTG International, Inc., a subsidiary of BTG plc (LSE: BTG plc (LSE: BGC). He serves as non executive director in the Janus Board